June 17, 2019
Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis
Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).